Evidence map›Paper›PMID 33097091›Full record

ArticleEpigenetics & chromatin2020

The histone and non-histone methyllysine reader activities of the UHRF1 tandem Tudor domain are dispensable for the propagation of aberrant DNA methylation patterning in cancer cells.

Robert M Vaughan, Ariana Kupai, Caroline A Foley, Cari A Sagum, Bailey M Tibben, Hope E Eden, Rochelle L Tiedemann, Christine A Berryhill, Varun Patel, Kevin M Shaw and 6 more

Open access · goldAbstract read
In one paragraph

Article in Epigenetics & chromatin, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Robert M VaughanCenter for Epigenetics, Van Andel Institute, Grand Rapids, MI, 49503, USA.
Ariana KupaiCenter for Epigenetics, Van Andel Institute, Grand Rapids, MI, 49503, USA.
Caroline A FoleyCenter for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina At Chapel Hill, Chapel Hill, NC, 27599, USA.
Cari A SagumDepartment of Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Smithville, TX, 78957, USA.
Bailey M TibbenCenter for Epigenetics, Van Andel Institute, Grand Rapids, MI, 49503, USA.
Hope E EdenCenter for Epigenetics, Van Andel Institute, Grand Rapids, MI, 49503, USA.
Rochelle L TiedemannCenter for Epigenetics, Van Andel Institute, Grand Rapids, MI, 49503, USA.
Christine A BerryhillCenter for Epigenetics, Van Andel Institute, Grand Rapids, MI, 49503, USA.
Varun PatelCenter for Epigenetics, Van Andel Institute, Grand Rapids, MI, 49503, USA.
Kevin M ShawCenter for Epigenetics, Van Andel Institute, Grand Rapids, MI, 49503, USA.
Krzysztof KrajewskiDepartment of Biochemistry and Biophysics, University of North Carolina At Chapel Hill, Chapel Hill, NC, 27599, USA.
Brian D StrahlDepartment of Biochemistry and Biophysics, University of North Carolina At Chapel Hill, Chapel Hill, NC, 27599, USA.
Mark T BedfordDepartment of Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Smithville, TX, 78957, USA.
Stephen V FryeCenter for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina At Chapel Hill, Chapel Hill, NC, 27599, USA.
Bradley M DicksonCenter for Epigenetics, Van Andel Institute, Grand Rapids, MI, 49503, USA.
Scott B RothbartCenter for Epigenetics, Van Andel Institute, Grand Rapids, MI, 49503, USA. scott.rothbart@vai.org.ORCID 0000-0003-1631-5392
Van Andel Institute · USUniversity of North Carolina at Chapel Hill · USThe University of Texas MD Anderson Cancer Center · US

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
Molecular mechanisms of chromatin and epigenetic regulationR35GM124736 · NIGMS · VAN ANDEL RESEARCH INSTITUTE · PI ROTHBART, SCOTT · 2017 to 2021
$2.4M
The Functional Analysis of the Coactivator CARM1R01GM126421 · NIGMS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BEDFORD, MARK T. · 2018 to 2021
$1.4M
Modulating the DNA methylation program through UHRF1 antagonismR21CA216673 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI FRYE, STEPHEN VERNON, STRAHL, BRIAN D · 2018 to 2019
$396k
DNA methylation regulation through the UHRF1 oncoproteinF99CA245821 · NCI · VAN ANDEL INSTITUTE GRADUATE SCHOOL · PI VAUGHAN, ROBERT MARK · 2019 to 2020
$90k
Cancer Prevention and Research Institute of Texas RP 180804NCI NIH HHS F99 CA245821NCI NIH HHS P30 CA016086NCI NIH HHS R21 CA216673NIGMS NIH HHS R01 GM126421NIGMS NIH HHS R35 GM124736
6 · The paper itself

Abstract

The chromatin-binding E3 ubiquitin ligase ubiquitin-like with PHD and RING finger domains 1 (UHRF1) contributes to the maintenance of aberrant DNA methylation patterning in cancer cells through multivalent histone and DNA recognition. The tandem Tudor domain (TTD) of UHRF1 is well-characterized as a reader of lysine 9 di- and tri-methylation on histone H3 (H3K9me2/me3) and, more recently, lysine 126 di- and tri-methylation on DNA ligase 1 (LIG1K126me2/me3). However, the functional significance and selectivity of these interactions remain unclear. In this study, we used protein domain microarrays to search for additional readers of LIG1K126me2, the preferred methyl state bound by the UHRF1 TTD. We show that the UHRF1 TTD binds LIG1K126me2 with high affinity and selectivity compared to other known methyllysine readers. Notably, and unlike H3K9me2/me3, the UHRF1 plant homeodomain (PHD) and its N-terminal linker (L2) do not contribute to multivalent LIG1K126me2 recognition along with the TTD. To test the functional significance of this interaction, we designed a LIG1K126me2 cell-penetrating peptide (CPP). Consistent with LIG1 knockdown, uptake of the CPP had no significant effect on the propagation of DNA methylation patterning across the genomes of bulk populations from high-resolution analysis of several cancer cell lines. Further, we did not detect significant changes in DNA methylation patterning from bulk cell populations after chemical or genetic disruption of lysine methyltransferase activity associated with LIG1K126me2 and H3K9me2. Collectively, these studies identify UHRF1 as a selective reader of LIG1K126me2 in vitro and further implicate the histone and non-histone methyllysine reader activity of the UHRF1 TTD as a dispensable domain function for cancer cell DNA methylation maintenance.

Indexed as

DNA MethylationGene Expression Regulation, NeoplasticHistone CodeCCAAT-Enhancer-Binding ProteinsEpigenesis, GeneticHCT116 CellsHeLa CellsHistonesHumansLysineMethylationProtein Processing, Post-TranslationalTudor DomainUbiquitin-Protein LigasesCCAAT-Enhancer-Binding ProteinsHistonesLysineUbiquitin-Protein LigasesUHRF1 protein, human

Identifiers

PMID33097091
PMCPMC7585203
OpenAlexW3093878567

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.